COVID-19 Outcomes in Inflammatory Bowel Disease Hospitalized Patients: A Comprehensive Analysis Using the National Inpatient Sample.

IF 1.4 Q4 GASTROENTEROLOGY & HEPATOLOGY Gastroenterology Research Pub Date : 2023-10-01 Epub Date: 2023-10-21 DOI:10.14740/gr1657

Justin M Joseph, Anum Akhlaq, Rehmat Ullah Awan, Saleha Aziz, Moon Ryu, Asif Farooq, Karthik Gangu, Ehizogie Edigin, Abu Baker Sheikh

{"title":"COVID-19 Outcomes in Inflammatory Bowel Disease Hospitalized Patients: A Comprehensive Analysis Using the National Inpatient Sample.","authors":"Justin M Joseph, Anum Akhlaq, Rehmat Ullah Awan, Saleha Aziz, Moon Ryu, Asif Farooq, Karthik Gangu, Ehizogie Edigin, Abu Baker Sheikh","doi":"10.14740/gr1657","DOIUrl":null,"url":null,"abstract":"Background: There is no uniformity in the available literature concerning the effects of coronavirus disease 2019 (COVID-19) viral illness on people with inflammatory bowel disease (IBD).Methods: We conducted an analysis using the 2020 National Inpatient Sample (NIS) database to compare the outcomes of COVID-19 hospitalized patients with and without IBD.Results: Of 1,050,040 patients admitted with COVID-19, 5,750 (0.5%) also had IBD. The group with COVID-19 and IBD had higher percentages of females and White individuals and a greater prevalence of chronic lung disease, peripheral vascular disease, and liver disease. However, after accounting for confounding variables, there was no significant difference in mortality rates, length of hospital stays, or hospitalization costs between the two groups.Conclusion: According to our findings, the presence of IBD does not appear to elevate the risk of COVID-19 complications.","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"16 5","pages":"262-269"},"PeriodicalIF":1.4000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627357/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/gr1657","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: There is no uniformity in the available literature concerning the effects of coronavirus disease 2019 (COVID-19) viral illness on people with inflammatory bowel disease (IBD).

Methods: We conducted an analysis using the 2020 National Inpatient Sample (NIS) database to compare the outcomes of COVID-19 hospitalized patients with and without IBD.

Results: Of 1,050,040 patients admitted with COVID-19, 5,750 (0.5%) also had IBD. The group with COVID-19 and IBD had higher percentages of females and White individuals and a greater prevalence of chronic lung disease, peripheral vascular disease, and liver disease. However, after accounting for confounding variables, there was no significant difference in mortality rates, length of hospital stays, or hospitalization costs between the two groups.

Conclusion: According to our findings, the presence of IBD does not appear to elevate the risk of COVID-19 complications.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

炎症性肠病住院患者的新冠肺炎结局：使用全国住院患者样本的综合分析。

背景：关于2019冠状病毒病（新冠肺炎）病毒性疾病对炎症性肠病（IBD）患者的影响的现有文献并不一致新冠肺炎患者中也有5750人（0.5%）患有IBD。新冠肺炎和IBD患者中女性和白人的比例较高，慢性肺病、外周血管病和肝病的患病率较高。然而，在考虑了混杂变量后，两组之间的死亡率、住院时间或住院费用没有显著差异。结论：根据我们的研究结果，IBD的存在似乎不会增加新冠肺炎并发症的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Gastroenterology Research GASTROENTEROLOGY & HEPATOLOGY-

自引率

0.00%

发文量